Production (Stage)
Hepion Pharmaceuticals, Inc.
HEPA
$0.0722
$0.009214.60%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -29.85% | 5.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.52% | -73.03% | |||
| Operating Income | -6.52% | 73.03% | |||
| Income Before Tax | -294.57% | 68.20% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -294.57% | 68.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -294.57% | 68.20% | |||
| EBIT | -6.52% | 73.03% | |||
| EBITDA | -5.88% | 73.03% | |||
| EPS Basic | 80.62% | 69.33% | |||
| Normalized Basic EPS | 97.55% | 48.78% | |||
| EPS Diluted | 80.62% | 69.33% | |||
| Normalized Diluted EPS | 97.55% | 48.78% | |||
| Average Basic Shares Outstanding | 1,936.40% | 3.65% | |||
| Average Diluted Shares Outstanding | 1,936.40% | 3.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||